Prevention strategies for blood-borne viruses—in the Era of vaccines, direct acting antivirals and antiretroviral therapy

Reviews in Medical Virology

Volumn 26, Issue 5, 2016, Pages 330-339

  Pfaender, Stephanie ^a,b,c,d   von Hahn, Thomas ^e,f   Steinmann, Joerg ^g   Ciesek, Sandra ^g   Steinmann, Eike ^a,b  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f German Center for Infection Research (DZIF) Hannover Braunschweig Site   (Switzerland)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; VIRUS VACCINE;

ANTIVIRAL THERAPY; AWARENESS; BLOOD; DISINFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYGIENE; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATIENT COUNSELING; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; REVIEW; SCREENING; SECONDARY PREVENTION; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 84985992312     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1890     Document Type: Review

References (78)

1. Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, Bouvet E, Yazdanpanah Y. Blood-borne viruses in health care workers: prevention and management. Journal of Clinical Virology 2011; 52: 4–10. DOI:10.1016/j.jcv.2011.05.016.
2. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet (London, England) 2012; 379: 2477–2488.
3. HIV/AIDS Fact Sheet N°360 [Media centre]. http://www.who.int/mediacentre/factsheets/fs360/en/ [accessed 12 November 2015].
4. Hepatitis B Fact Sheet N°204 [Media centre]. http://www.who.int/mediacentre/factsheets/fs204/en/ [accessed 12 November 2015].
5. Hepatitis C Fact Sheet N°164 [Media centre]. http://www.who.int/mediacentre/factsheets/fs164/en/ [accessed 12 November 2015].
6. Hepatitis E Fact Sheet N°280 [Media centre]. http://www.who.int/mediacentre/factsheets/fs280/en/ [accessed 12 November 2015].
7. Benjamin RM. Raising awareness of viral hepatitis: National Hepatitis Testing Day, May 19. Public Health Reports 2012; 127: 244–245.
8. Prevention and control of viral hepatitis infection: framework for global action. http://www.who.int/hiv/pub/hepatitis/Framework/en/ [accessed 20 January 2016].
9. Viral Hepatitis—Hepatitis B Information. http://www.cdc.gov/hepatitis/hbv/index.htm [accessed 20 January 2016].
10. Behrendt P, Steinmann E, Manns MP, Wedemeyer H. The impact of hepatitis E in the liver transplant setting. Journal of Hepatology 2014; 61: 1418–1429. DOI:10.1016/j.jhep.2014.08.047.
11. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clinical Microbiology Reviews 2014; 27: 116–138. DOI:10.1128/CMR.00057-13.
12. Pawlotsky JM. Hepatitis E screening for blood donations: an urgent need? Lancet 2014; 384: 1729–1730. DOI:10.1016/S0140-6736(14)61187-9.
13. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 2001; 91: 42–46.
14. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization 2013; 91: 102–123. DOI:10.2471/Blt.12.108282.
15. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571–583. DOI:10.1016/S0140-6736(11)61097-0.
16. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infectious Diseases 2006; 6: 726–732. DOI:10.1016/S1473-3099(06)70629-6.
17. Mohan N, Gonzalez-Peralta RP, Fujisawa T, et al. Chronic hepatitis C virus infection in children. Journal of Pediatric Gastroenterology and Nutrition 2010; 50: 123–131. DOI:10.1097/MPG.0b013e3181c61995.
18. Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. Journal of Hepatology 1998; 29: 191–197.
19. de Oliveira PR, Yamamoto AY, de Souza CBS, et al. Hepatitis B viral markers in banked human milk before and after holder pasteurization. Journal of Clinical Virology 2009; 45: 281–284. DOI:10.1016/j.jcv.2009.04.003.
20. Shi ZJ, Yang YB, Wang H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus a meta-analysis and systematic review. Archives of Pediatrics & Adolescent Medicine 2011; 165: 837–846. DOI:10.1001/archpediatrics.2011.72.
21. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001; 15: 837–845.
22. Ackerman Z, Paltiel O, Glikberg F, Ackerman E. Hepatitis C virus in various human body fluids: a systematic review. Hepatology Research 1998; 11: 26–40. DOI:10.1016/S1386-6346(98)00004-7.
23. Komatsu H, Inui A, Sogo T, Tateno A, Shimokawa R, Fujisawa T. Tears from children with chronic hepatitis B virus (HBV) infection are infectious vehicles of HBV transmission: experimental transmission of HBV by tears, using mice with chimeric human livers. Journal of Infectious Diseases 2012; 206: 478–485. DOI:10.1093/infdis/jis293.
24. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clinical Microbiology Reviews 2000; 13: 385–407.
25. Gerberding JL. Management of occupational exposures to blood-borne viruses. New England Journal of Medicine 1995; 332: 444–451. DOI:10.1056/NEJM199502163320707.
26. Service USPH. Updated U.S. Public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR - Recommendations and Reports 2001; 50: 1–52.
27. Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don't physicians test for HIV? A review of the US literature. AIDS 2007; 21: 1617–1624. DOI:10.1097/QAD.0b013e32823f91ff.
28. Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update. Clinical Infectious Diseases 2012; 55(Suppl 1): S49–53. DOI:10.1093/cid/cis363.
29. Coste J, Reesink HW, Engelfriet CP, et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sanguinis 2005; 88: 289–303. DOI:10.1111/j.1423-0410.2005.00636_1.x.
30. Baylis SA, Gartner T, Nick S, Ovemyr J, Blumel J. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sanguinis 2012; 103: 89–90. DOI:10.1111/j.1423-0410.2011.01583.x.
31. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17: 1730–1733.
32. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clinical Infectious Diseases 2012; 54: 1167–1178. DOI:10.1093/cid/cir991.
33. Scott-Sheldon LAJ, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. Jaids-Journal of Acquired Immune Deficiency Syndromes 2011; 58: 489–498. DOI:10.1097/QAI.0b013e31823554d7.
34. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database of Systematic Reviews 2009 ARTN CD003362. DOI:10.1002/14651858.CD003362.pub2.
35. Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infectious Diseases 2012; 12: 289. DOI:10.1186/1471-2334-12-289.
36. Hagan H, Jarlais DCD. HIV and HCV infection among injecting drug users. Mount Sinai Journal of Medicine 2000; 67: 423–428.
37. Larney S, Grebely J, Falster M, et al. Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study. Drug and Alcohol Dependence 2015; 148: 213–216. DOI:10.1016/j.drugalcdep.2014.12.027.
38. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (Abingdon, England) 2010; 105: 844–859.
39. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews 2011; CD003510. DOI:10.1002/14651858.CD003510.pub3.
40. Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology 2016; 63: 319–333. DOI:10.1002/hep.28302.
41. EACS Guidelines 8.0. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html [accessed 20 January 2016].
42. Clinical Guidelines Portal. https://aidsinfo.nih.gov/guidelines [20 January 2016].
43. Jain S, Mayer KH. Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. AIDS 2014; 28: 1545–1554. DOI:10.1097/QAD.0000000000000301.
44. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine (London) 2011; 61: 531–540. DOI:10.1093/occmed/kqr136.
45. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014 Clinical Practice Guideline. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf [accessed 20 January 2016].
46. Romano L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Digestive and Liver Disease 2011; 43(Suppl 1): S2–7. DOI:10.1016/S1590-8658(10)60685-8.
47. Trepo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet (London, England) 2014; 384: 2053–2063.
48. Viral hepatitis. http://www.cdc.gov/hepatitis/ [accessed 3 November 2015].
49. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. Journal of Hepatology 2014; 61: S34–44. DOI:10.1016/j.jhep.2014.09.009.
50. Man John Law L, Landi A, Magee WC, Lorne Tyrrell D, Houghton M. Progress towards a hepatitis C virus vaccine. Emerging Microbes & Infections 2013; 2: e79.
51. Mann JK, Ndung'u T. HIV-1 vaccine immunogen design strategies. Virology Journal 2015; 12: 3.
52. Cohen YZ, Dolin R. Novel HIV vaccine strategies: overview and perspective. Therapeutic Advances in Vaccines 2013; 1: 99–112.
53. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS 2012; 26: 893–896. DOI:10.1097/QAD.0b013e328351f73f.
54. Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One 2015; 10: e0126920. DOI:10.1371/journal.pone.0126920.
55. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention. Annals of Internal Medicine 2012; 157 817-+:. DOI:10.7326/0003-4819-157-9-201211060-00529.
56. Alfaleh FZ, Nugrahini N, Maticic M, et al. Strategies to manage hepatitis C virus infection disease burden—volume 3. Journal of Viral Hepatitis 2015; 22(Suppl 4): 42–65. DOI:10.1111/jvh.12474.
57. Ryom L, Boesecke C, Gisler V, et al. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Medicine 2015. DOI:10.1111/hiv.12322.
58. Clark DN, Hu J. Hepatitis B virus reverse transcriptase—target of current antiviral therapy and future drug development. Antiviral Research 2015; 123: 132–137. DOI:10.1016/j.antiviral.2015.09.011.
59. Zhang E, Kosinska A, Lu M, Yan H, Roggendorf M. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: search for the “magic bullet” to kill cccDNA. Antiviral Research 2015; 123: 193–203. DOI:10.1016/j.antiviral.2015.10.009.
60. Manns MP, von Hahn T. Novel therapies for hepatitis C—one pill fits all? Nature Reviews. Drug Discovery 2013; 12: 595–610. DOI:10.1038/nrd4050.
61. Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA. Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 2015; 7: 5206–5224. DOI:10.3390/v7102868.
62. European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2014. Journal of Hepatology 2014; 61: 373–395. DOI:10.1016/j.jhep.2014.05.001.
63. Sarrazin C, Berg T, Buggisch P, et al. S3 guideline hepatitis C addendum. Zeitschrift für Gastroenterologie 2015; 53: 320–334. DOI:10.1055/s-0034-1399322.
64. Solbach P, Wedemeyer H. The new era of interferon-free treatment of chronic hepatitis C. Viszeralmedizin 2015; 31: 290–296. DOI:10.1159/000433594.
65. Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine and Growth Factor Reviews 2014; 25: 369–376. DOI:10.1016/j.cytogfr.2014.07.015.
66. Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015; 61: 712–721. DOI:10.1002/hep.27323.
67. Peters van Ton AM, Gevers TJ, Drenth JP. Antiviral therapy in chronic hepatitis E: a systematic review. Journal of Viral Hepatitis 2015; 22: 965–973. DOI:10.1111/jvh.12403.
68. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338: 853–860. DOI:10.1056/Nejm199803263381301.
69. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Journal of Infectious Diseases 1999; 179: 717–720. DOI:10.1086/314623.
70. Buckhold FR. Primary care of the human immunodeficiency virus patient. Medical Clinics of North America 2015; 991105- +.:. DOI:10.1016/j.mcna.2015.05.010.
71. Robbins RN, Spector AY, Mellins CA, Remien RH. Optimizing ART adherence: update for HIV treatment and prevention. Current Hiv/Aids Reports 2014; 11: 423–433. DOI:10.1007/s11904-014-0229-5.
72. Geretti AM, Tsakiroglou M. HIV: new drugs, new guidelines. Current Opinion in Infectious Diseases 2014; 27: 545–553. DOI:10.1097/Qco.0000000000000106.
73. Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Current Opinion in Virology 2016; 18: 50–56. DOI:10.1016/j.coviro.2016.03.004.
74. Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long-acting injectable agents for HIV prevention. Current Opinion in HIV and AIDS 2016; 11: 122–128. DOI:10.1097/COH.0000000000000219.
75. Sherman EM, Worley MV, Unger NR, Gauthier TP, Schafer JJ. Cobicistat: review of a pharmacokinetic enhancer for HIV infection. Clinical Therapeutics 2015; 37: 1876–1893. DOI:10.1016/j.clinthera.2015.07.022.
76. Franco RA, Saag MS. When to start antiretroviral therapy: as soon as possible. BMC Medicine 2013; 11Artn 147:. DOI:10.1186/1741-7015-11-147.
77. WHO Guidelines Approved by the Guidelines Review Committee. In Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization Copyright (c) World Health Organization 2015.: Geneva, 2015.
78. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infectious Diseases 2014; 14: 281–290. DOI:10.1016/S1473-3099(13)70692-3.